At the time of study start (July 2023), the only available RCT evidence demonstrated a reduction in alcohol intake in response to GLP-1RAs only in people with obesity, so we focused our study on that population 19
2024;47(1):A372
Of particular interest are GLP-1/GCG dual-receptor agonists, especially those targeting GLP-1, GIP, and GCG receptors simultaneously.214,215 The activation of GCG receptors is hypothesized to enhance energy expenditure, thereby facilitating weight reduction.216 It is well established that GCG exerts hyperglycemic effects by stimulating hepatic gluconeogenesis, which may be detrimental in diabetic patients
We review the medical history, baseline labs, weight-related conditions, medication risks, side effects, insurance barriers, muscle preservation, and the long-term maintenance plan
Visit lajollarecovery.com to learn more